Nuevolution announces the publication of a scientific article in collaboration with Nobel Laureate Dr. Robert J. Lefkowitz

Stockholm, 23 January 2017. Nuevolution AB (publ) (NUE.ST) today announced the publication of the scientific article entitled “An allosteric “Beta-Blocker” isolated from a DNA-encoded small molecule library” in the Proceedings of the National Academy of Sciences, USA.

The article presents work from the ongoing collaboration between Nuevolution and the group of Nobel Laureate Dr. Robert J. Lefkowitz at Duke University involving the screening of Nuevolution compound libraries against an important class of targets named GPCRs involved in signaling across cell-membranes. The results of the collaboration provide Nuevolution with attractive methods for the screening of challenging membrane bound targets.

“The collaboration with Dr Lefkowitz’ group is focused on answering some of the fundamental details of signalling through GPCR receptors, and we are very excited to see some of the joint work now being published” said Thomas Franch, CSO of Nuevolution and continued “We look forward to continuing the productive research collaboration with the Lefkowitz group to further expand the applicability of our technology to difficult membrane bound targets, and to seek answers and understand the details of GPCR receptor signalling mechanisms”.

  

For more information, please contact:

Thomas Franch, CSO
Phone: +45 7020 0987
Email: [email protected]

Henrik D. Simonsen, CFO
Phone: +45 3913 0947
Email: [email protected]

 

About Chemetics™

The Nuevolution Chemetics™ technology comprises proprietary methods enabling DNA-encoding of fragments and combinatorial chemistry libraries for fast and cost efficient screening of disease targets. Nuevolution annually produces 4-8 Chemetics™ libraries comprising millions to multi billions of compounds per library. For further details about Chemetics™, please visit: www.nuevolution.com.

About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

This information is information that Nuevolution AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on Monday 23 January 2017, 21:00 CET.

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Redeye AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found at: www.nuevolution.com.